• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Steris, Synergy Health to contest FTC move to block merger

Steris, Synergy Health to contest FTC move to block merger

May 29, 2015 By Brad Perriello

Steris, Synergy Health to contest FTC move to block merger

(Reuters) — Steris (NYSE:STE) and Synergy Health said they would contest the U.S. Federal Trade Commission’s attempt to block Steris’s acquisition of the British company.

The companies said they were confident the court would reject the FTC’s request for an injunction blocking the merger.

“We are very disappointed by the FTC’s decision to impede this transaction and intend to vigorously challenge their claims in court,” Synergy CEO Richard Steeves said in a statement.

Synergy shares fell as much as 6.2% in early trading, making it the top loser on the FTSE-250 Midcap Index this morning.

A number of “inversion” deals – which allow companies to escape higher taxes in the U.S. by reincorporating abroad – have come undone in the past few months after the U.S. Treasury Dept. tightened its rules.

Steris offered to buy Synergy for about $1.9 billion in October, after the new rules were announced, in a deal that would allow the U.S.-based company to shift its domicile to the U.K. and cut its tax bill.

Steris said in a separate statement that the companies had not yet seen the FTC announcement or formal complaint, but welcomed a full judicial review of the competitive effects of the combination.

“We have worked diligently to address the FTC’s concerns and to avoid litigation, but we will now focus our efforts on prevailing in court,” Steris CEO Walt Rosebrough said.

The deal has been hanging in the balance since the FTC began reviewing it in October. The companies said in mid-January that the FTC had requested additional information and documentary material related to the deal, effectively extending the initial deal closing of March 31. In March the companies postponed a shareholder vote on their proposed merger in order to comply with an information request from the FTC. U.K. regulators approved the deal in February.

Synergy and Steris said on Friday that they planned to extend the completion date to Dec. 31.

Synergy shares were down 1.7% at £18.61 at 9:09 GMT. The stock has lost more than 16% in the last 3 days on doubts of the deal going through.

Steris shares have lost 4.3% during the same period. They closed at $66.15 yesterday on the New York Stock Exchange.

Filed Under: News Well

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy